Melanoma Clinical Trial

Clinical Trial Finder Melanoma Trials

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

See Locations Near You

Summary

The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated

View Eligibility Criteria

Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

12 years and older unless not permitted by local regulations; in that case 18 years old and older
Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1
Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)
Treatment-naïve participants (no prior systemic anticancer therapy for unresectable or metastatic melanoma)
Measurable disease per RECIST v1.1

Exclusion Criteria:

Active brain metastases or leptomeningeal metastases
Uveal or ocular melanoma
Participants with active, known, or suspected autoimmune disease
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

20

Study ID:

NCT03329846

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 59 Locations for this study

See Locations Near You

Angeles Clinic and Research Institute
Los Angeles California, 90025, United States
University Of Colorado
Aurora Colorado, 80045, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach Florida, 33140, United States
University Of Chicago
Chicago Illinois, 60637, United States
Oregon Health & Science University
Portland Oregon, 97239, United States
Local Institution
Seattle Washington, 98109, United States
Local Institution
Blacktown New South Wales, 2148, Australia
Melanoma Institute Australia
North Sydney New South Wales, 2146, Australia
Local Institution
Greenslopes Queensland, 4120, Australia
Local Institution
Woolloongabba Queensland, 4120, Australia
Local Institution
Box Hill Victoria, 3128, Australia
Local Institution
Melbourne Victoria, 3000, Australia
Local Institution
Melbourne Victoria, 3004, Australia
Local Institution
Montreal Quebec, H3T 1, Canada
Local Institution
Quebec , G1R 2, Canada
Klinika onkologie a radioterapie
Hradec Kralove , 500 0, Czechia
Dermatovenerologicka klinika 3. LF UK a FNKV
Praha 10 , 100 3, Czechia
Dermatovenerologicka klinika VFN a 1. LF UK
Praha 2 , 128 0, Czechia
Local Institution
Boulogne-billancourt , 92104, France
Local Institution
Saint Etienne Cedex 2 , 42055, France
Local Institution
Villejuif Cedex , 94805, France
Elbe Klinikum Buxtehude
Buxtehude , 21614, Germany
Universitaetsklinikum Carl Gustav Carus
Dresden , 01307, Germany
Local Institution
Essen , 45147, Germany
SRH Wald-Kliniken Gera GmbH
Gera , , Germany
Georg August Universitaet Goettingen
Goettingen , 37075, Germany
Local Institution
Hannover , 30625, Germany
Local Institution
Heidelberg , 69120, Germany
Local Institution
Muenchen , 80337, Germany
Local Institution
Tuebingen , 72076, Germany
Interbalkan European Medical Center
Thessaloniki , 57001, Greece
Local Institution
Dooradoyle Limerick, , Ireland
Local Institution
Dublin , 4, Ireland
Local Institution
Dublin , 7, Ireland
Local Institution
Milano , 20133, Italy
Istituto Nazionale Tumori Fondazione Pascale
Napoli , 80131, Italy
Azienda Ospedaliera Universitaria Senese
Siena , 53100, Italy
Local Institution
Sendai-shi Miyagi, 98085, Japan
Local Institution
Niigata-shi Niigata, 95185, Japan
Local Institution
Okayama-shi Okayama, 70009, Japan
Local Institution
Osaka-shi Osaka, 54185, Japan
Local Institution
Chuo-ku Tokyo, 10400, Japan
Local Institution
Amsterdam , 1066 , Netherlands
Local Institution
Groningen , 9700R, Netherlands
Local Institution
Nijmegen , 6525 , Netherlands
Local Institution
Rotterdam , 3008 , Netherlands
Local Institution
Christchurch , , New Zealand
Local Institution
Wellington , 6021, New Zealand
Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
Warszawa , 02-78, Poland
Local Institution
Barcelona , 08036, Spain
Local Institution
Jaen , 23007, Spain
Local Institution
Madrid , 28007, Spain
Local Institution
Malaga , 29010, Spain
Local Institution
Santiago Compostela , 15706, Spain
Local Institution
Valencia , 46026, Spain
Universitaetsspital Zuerich
Zürich , 8091, Switzerland
Local Institution
London Greater London, SW17 , United Kingdom
Local Institution
London Greater London, SW3 6, United Kingdom
Local Institution
Belfast , BT9 7, United Kingdom
Local Institution
Cambridge , CB2 0, United Kingdom
Local Institution
Cottingham , HU16 , United Kingdom
Local Institution
Manchester , M20 4, United Kingdom
Local Institution
Tauton , TA1 5, United Kingdom
Load More

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

20

Study ID:

NCT03329846

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider